MariTide · MARITIME-CV
Amgen identifies MARITIME-CV as enrolling in its 2026 update. Cardiovascular outcome success is distinct from previously reported weight-loss results. maridebart cafraglutide — phase 3 study in Atherosclerotic Cardiovascular Disease, Overweight, Obesity. NCT07037433 lists Time to First Occurrence of a Composite Endpoint Consisting of: CV Death, Myocardial Infarction (MI), or Ischemic Stroke (3-point Major Adverse Cardiac Events [3-P MACE]) as a primary outcome (Up to approximately 35 months). Registry status: active not recruiting.
What matters
Track what the company has actually announced, the study or asset involved, and the evidence needed to confirm the milestone.
- Specify the exact future analysis/cohort and verify that it remains unpublished before creating any tradeable question.
- Registry design and recruitment status are not evidence of efficacy or regulatory approval.
- Primary completion is not a guaranteed topline publication or regulatory decision date.
- Registry primary completion: 2028-06-30 (estimated); verify independently before using it as a catalyst date.
- An active study record does not establish that its primary outcome is still unannounced. Review sponsor disclosures before promotion to a future catalyst.
- The registry lists 2 primary outcome measures. A market must explicitly specify which endpoint or conjunction resolves YES; this card highlights one measure only.
Primary evidence
Long-horizon CV study — result date not confirmed
Potential outcome market
Will maridebart cafraglutide meet the prespecified primary endpoint in NCT07037433 by a listing deadline still to be specified?
This event is research, not a listed market. A market needs a precise question, resolution rules and liquidity before trading opens.